# Dasotraline Pediatric ADHD Study

> **NCT02428088** · PHASE2,PHASE3 · COMPLETED · sponsor: **Sumitomo Pharma America, Inc.** · enrollment: 330 (actual)

## Conditions studied

- Attention Deficit Hyperactivity Disorder

## Interventions

- **DRUG:** Dasotraline
- **DRUG:** Dasotraline
- **DRUG:** Placebo Comparator

## Key facts

- **NCT ID:** NCT02428088
- **Lead sponsor:** Sumitomo Pharma America, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-04
- **Primary completion:** 2016-07
- **Final completion:** 2016-07
- **Target enrollment:** 330 (ACTUAL)
- **Last updated:** 2021-03-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02428088

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02428088, "Dasotraline Pediatric ADHD Study". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT02428088. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*